<DOC>
	<DOCNO>NCT00003788</DOCNO>
	<brief_summary>RATIONALE : Photodynamic therapy use light drug make cancer cell sensitive light kill tumor cell . It yet know addition photodynamic therapy combine therapy surgery , radiation therapy , chemotherapy effective combined therapy alone supratentorial glioma . PURPOSE : Randomized phase III trial study effectiveness surgery , radiation therapy , chemotherapy without photodynamic therapy treat patient newly diagnose recurrent malignant supratentorial glioma .</brief_summary>
	<brief_title>Surgery , Radiation Therapy , Chemotherapy With Without Photodynamic Therapy Treating Patients With Newly Diagnosed Recurrent Malignant Supratentorial Gliomas</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether addition photodynamic therapy standard brain tumor care ( surgical resection , postoperative radiotherapy , chemotherapy ) result significant prolongation time recurrence survival newly diagnose malignant supratentorial glioma . - Compare effect high low light dose photodynamic therapy survival patient recurrent malignant supratentorial glioma . OUTLINE : This randomize , multicenter , two part study . Patients stratify accord clinical center . Newly diagnose patient ( Study 1 ) - Patients randomize receive either high light dose photodynamic therapy ( arm I ) photodynamic therapy ( arm II ) : - Arm I : Patients receive porfimer sodium ( Photofrin ) IV one day prior surgery . Craniotomy tumor resection perform . Upon completion resection , patient undergo intracavitary photoillumination high light dose . - Arm II : Craniotomy tumor resection perform . Postoperatively , patient receive external beam radiotherapy 5 day per week 5-6 week . After complete radiotherapy , patient receive nitrosourea ( carmustine lomustine ) chemotherapy . Recurrent tumor patient ( Study 2 ) - Patients receive Photofrin IV one day prior surgery . Craniotomy tumor resection perform . - Arm I : Patients receive high dose light therapy surgery . - Arm II : Patients receive low dose light therapy surgery . Patients receive chemotherapy procarbazine 28 day begin 2-4 week surgery . Courses repeat every 56 day absence disease progression unacceptable toxicity . Patients follow study 4 week postsurgery , every 3 month death 1 year study closure . PROJECTED ACCRUAL : A minimum 150 patient newly diagnose tumor accrue study within 4 year ( Study 1 ) . A maximum 120 patient recurrent disease accrue within 4.5 year ( Study 2 )</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Dihematoporphyrin Ether</mesh_term>
	<mesh_term>Trioxsalen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose recurrent supratentorial glioblastoma malignant astrocytoma Grade 3 4 astrocytoma define DaumasDuport classification Suitable radical resection basis image study Patients recurrent disease must fail surgery radiotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % newly diagnose tumor Karnofsky 70100 % recurrent tumor Life expectancy : At least 3 month Hematopoietic : Recurrent tumor : WBC least 2,000/mm^3 Platelet count least 80,000/mm^3 Hepatic : Recurrent tumor : PT/PTT great 1.5 time upper limit normal ( ULN ) Bilirubin LFTs less 2 time ULN Alkaline phosphatase great 3 time ULN GGT great 3 time ULN Renal : Creatinine great 2 mg/dL Other : Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior cranial radiotherapy newly diagnose tumor Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>